bioAffinity Technology启动180万美元直接融资

2025-10-09 04:31

bioAffinity Technologies (NASDAQ:BIAF) has entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007 per share, at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq rules.
The gross proceeds from the offering are expected to be about $1.8 million. The company intends to use the net proceeds from the offering for working capital, to support expected growing sales for CyPath® Lung, its noninvasive test for lung cancer, and general corporate purposes.
The closing of the offering is expected to occur on or about October 9, 2025.
BIAF -3.60% after hours to $2.94.
Source: Press Release

More on bioAffinity Technologies